Xcovery set to begin Phase I/II AMD trial with oral drug candidate

Article

Xcovery Holdings starts Phase I/II trials of oral angiogenesis inhibitor, X-82, for neovascular wet age-related macular degeneration (AMD).

Xcovery Holdings will begin Phase I/II clinical trials of its oral angiogenesis inhibitor, X-82, for the treatment of neovascular wet age-related macular degeneration (AMD).

The initial Phase I/II trial will assess the preliminary safety and tolerability of X-82, a tyrosine kinase inhibitor (TKI) in an oral formulation that acts by blocking pathologic blood vessel growth. The trial will enroll a maximum of 20 patients and will be conducted at three ophthalmology centers in the U.S.

"The potential for an oral treatment for wet AMD is considered the ultimate therapeutic option for these patients," said Sheridan "Sherry" G. Snyder, Xcovery Holdings Chairman and CEO. "We are committed to providing better therapies to patients with advanced eye disease and this trial represents an important advancement in Xcovery Vision's clinical development program."

X-82 inhibits both vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), two important targets implicated in wet AMD. The compound has been designed to have a favorable toxicity profile and better tolerability as an oral medication than previous injectable drugs in this class.

"There is growing evidence that combined inhibition of VEGF and PDGF may have advantages over existing anti-VEGF therapies," said Jeffrey S. Heier, MD, head of Xcovery Vision's advisory board and co-director, Tufts/OCB Vitreoretinal Fellowship at Massachusetts General Hospital. "And the prospect of an oral therapy for wet AMD is appealing to patients who may prefer taking a pill instead of an eye injection."

Kenneth J. Mandell, MD, PhD, president and COO of Xcovery Vision added, "Unlike current anti-VEGF injections that only treat the affected eye, our oral pill has the potential to prevent development of wet AMD in the opposite eye before disease progression."


Related Articles

New data confirm efficacy, safety of ranibizumab

Anti-PDGF, anti-VEGF combination demonstrates superior efficacy for wet AMD

New OCT parameters associated with wet AMD risk

Bayer to launch AMD drug in Australia

FDA approves therapies for AMD, insomnia

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.